This decision to recommend the drug as a cost-effective use of NHS resources follows the submission of new evidence from the company during consultation on earlier draft recommendations.
Amgen has a confidential commercial arrangement which will make the drug available to the NHS with a discount.
The use of Blincyto compared to continued chemotherapy may reduce MRD and help increase the time people have without their disease relapsing. People with lower MRD levels have a higher chance of their disease being cured after stem cell transplantation.
Administration is by continuous intravenous infusion delivered at a constant rate using an infusion pump. A single cycle of the treatment comprises continuous intravenous infusion at a dose of 28 micrograms/day for 28 days, followed by a 14‑day treatment-free interval…